

## PLASMIC score de prédiction d'un PTT

En cas de MAT associant une anémie hémolytique, mécanique (avec des schizocytes, sans notion de %) et une thrombopénie, le PLASMIC score aide à prédire un déficit sévère en ADAMTS13 (PTT) et à porter l'indication d'EP.

Score à utiliser avec « un bon sens clinique », difficile à interpréter par exemple chez un patient cirrhotique ictérique qui peut malgré tout avoir un vrai PTT

	Points*
Platelet count $<30 \times 10^9$ per L	1
Haemolysis variable†	1
No active cancer	1
No history of solid-organ or stem-cell transplant	1
MCV $<90$ fL‡	1
INR $<1.5$	1
Creatinine $<2.0$ mg/dL	1

INR=international normalised ratio. MCV=mean corpuscular volume. \* Score of 0–4 denotes low risk for severe ADAMTS13 deficiency; score of 5 denotes intermediate risk; score of 6 or 7 denotes high risk. †Reticulocyte count  $>2.5\%$ , or haptoglobin undetectable, or indirect bilirubin  $>2.0$  mg/dL. ‡ $<9.0 \times 10^{-14}$  L.

**Table 3: The PLASMIC score for prediction of thrombotic microangiopathy associated with severe ADAMTS13 deficiency**

	Derivation cohort (n=200)	Internal validation cohort (n=150)	External validation cohort (n=146)
0–4	0/84 (0%)	0/89 (0%)	2/47 (4%)
5	2/44 (5%)	3/32 (9%)	6/25 (24%)
6 or 7	58/72 (81%)	18/29 (62%)	61/74 (82%)

Data are number of individuals with ADAMTS13 activity of 10% or less/total number of individuals with that score (%).

**Table 4: Validation of the PLASMIC score**

**Table 6** Suggested management of adult patients with TMA (thrombocytopenia and schistocytosis) based on risk stratification

PLASMIC score	Probability of TTP <sup>a</sup>	Management
$<5$	Low: $<5\%$	Close observation Consider alternative diagnoses Send ADAMTS13 testing if no alternative cause identified
5	Intermediate: 5–25%	Send ADAMTS13 testing Obtain expert consultation Consider plasma infusion TPE if no other cause identified
$>5$	High: 60–80%	Send ADAMTS13 testing Obtain expert consultation Immediate TPE if high clinical suspicion for TTP

Abbreviations: TMA, thrombotic microangiopathy; TPE, therapeutic plasma exchange; TTP, thrombotic thrombocytopenic purpura.

<sup>a</sup>Quantitative risk estimates based on approximate probabilities observed in the PLASMIC derivation and validation cohorts.<sup>16</sup>